Diabetic Gastroparesis Study 2

CLINICAL STUDIES

A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis

Study Phase:	Phase 3
Criteria:	Male or Female 18 years or older T1DM or T2DM of at least 5 years duration. 3-month history of symptoms on an ongoing basis that are suggestive of GP (eg, nausea, abdominal pain, post-prandial fullness, bloating, vomiting, and early satiety)

Contact Us

(810) 237-1125

support@aamrc.net

Sign up Now

for receiving our monthly newsletter

CLINICAL STUDIES

Diabetic Gastroparesis Study 2

Study Phase:

Phase 3

Criteria:

Male or Female 18 years or older

T1DM or T2DM of at least 5 years duration.

3-month history of symptoms on an ongoing basis that are suggestive of GP (eg, nausea, abdominal pain, post-prandial fullness, bloating, vomiting, and early satiety)

What We Do

Quick links

Address

CLINICAL STUDIES

Diabetic Gastroparesis Study 2

Study Phase:

Phase 3

Criteria:

Male or Female 18 years or older T1DM or T2DM of at least 5 years duration. 3-month history of symptoms on an ongoing basis that are suggestive of GP (eg, nausea, abdominal pain, post-prandial fullness, bloating, vomiting, and early satiety)

Male or Female 18 years or older

T1DM or T2DM of at least 5 years duration.

3-month history of symptoms on an ongoing basis that are suggestive of GP (eg, nausea, abdominal pain, post-prandial fullness, bloating, vomiting, and early satiety)